Skye Bioscience Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
0.1%projected annual EPS growth
Analyst Coverage
5analysts covering
FY EPS (est.)
-$0.63next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Short-Term Investments Quarterly17.1MTarget: Sufficient capital to fund operations and key milestones through Q4 2026 (excluding proposed Phase 2b clinical and additional manufacturing costs)
Quarterly Net Loss Quarterly-12.5MTarget: Disciplined cost management to extend cash runway
Quarterly Research and Development (R&D) Expenses Quarterly7.9MTarget: Efficient allocation of capital toward nimacimab clinical development
Watch Items
- CBeyond Expansion Study (Part C) Topline DataTrigger: Q4 2026Action: Evaluate safety, tolerability, and exposure-response of higher-dose nimacimab to select the optimal dose for the planned Phase 2b combination trial.
- Cohort 2 Progression in CBeyond Expansion StudyTrigger: Cohort Review Committee approval based on safety dataAction: Monitor safety data from Cohort 1 to proceed with dose escalation and evaluate higher exposure levels.
- Capital Raising and Funding RunwayTrigger: Cash runway extending only through Q4 2026 (excluding Phase 2b costs)Action: Secure additional sources of capital or strategic partnerships to fund the upcoming Phase 2b clinical trial and related manufacturing.
Research as of 20 Jun 2026